Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Biochemical and Molecular Characterization of Marstacimab and TFPI Pathways
    Release Date:
    Review Process: Pfizer Internal
    Research Rare Disease Brazil, China, Germany, Italy, Japan, Korea, Netherlands, Saudi Arabia, Spain, Turkey, USA, United Kingdom
    Optimizing RSV diagnosis by improving RSV detection in patients admitted to ED/hospitalized due to respiratory symptoms
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Vaccines Austria, Belgium, Bulgaria, Czech Republic, Finland, Greece, Ireland, Israel, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Sweden, Switzerland
    Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence Approach
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology USA
    Guideline Concordant Care and Emerging Data for Patients with MIBC through la/mUC
    Release Date:
    Partner: Astellas
    Review Process: Pfizer Internal
    Education Oncology USA
    Advancing Genomic Competence and Patient Centered Care in Metastatic Breast Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Canada, China, France, Germany, India, Italy, Japan, Spain, United Kingdom
    AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug–Drug Interaction Management
    Release Date:
    Review Process: Pfizer Internal
    Research Internal Medicine Australia, Canada, Germany, Greece, Japan, Korea, Taiwan
    Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-posit
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology United States Minor Outlying I
    OPTIMA-HEMA Project: Optimizing the Management and Application of Novel Immunotherapies in Hematologic Malignancies
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology China
    Advancing Adult Immunization Strategies:A Focus on the Impact of Respiratory Syncytial Virus(RSV) and Cardiorespiratory Outcome
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines USA
    Implementing Shared Decision Making in Hemophilia Patient Care
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Rare Disease USA
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Life-Long Learning and Implementation of Education in Pain Associated with Osteoarthritis (Europe EFIC)
    Release Date:
    Partner:

    Lilly

    Review Process: Expert Review Panel
    Quality Improvement Internal Medicine Albania, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, France, Metropolitan, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Moldova, Republic of, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Slovakia (Slovak Republic), Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom
    Use of Biosimilar Agents in Inflammatory Conditions
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Diagnosis of Invasive Fungal Infections
    Release Date:
    Review Process: Pfizer Internal
    Education Hospital Afghanistan, Albania, Algeria, American Samoa, Andorra, Angola, Anguilla, Antarctica, Antigua and Barbuda, Argentina, Armenia, Aruba, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bermuda, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Bouvet Island, Brazil, British Indian Ocean Territory, Brunei Darussalam, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Canada, Cape Verde, Cayman Islands, Central African Republic, Chad, Chile, China, Christmas Island, Cocos (Keeling) Islands, Colombia, Comoros, Congo, Congo, The Democratic Republic, Cook Islands, Costa Rica, Cote D'ivoire, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Djibouti, Dominica, Dominican Republic, East Timor, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Ethiopia, Falkland Islands (Malvinas), Faroe Islands, Fiji, Finland, France, France, Metropolitan, French Guiana, French Polynesia, French Southern Territories, Gabon, Gambia, Georgia, Germany, Ghana, Gibraltar, Greece, Greenland, Grenada, Guadeloupe, Guam, Guatemala, Guinea, Guinea-bissau, Guyana, Haiti, Heard and Mc Donald Islands, Holy See (Vatican City State), Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran (Islamic Republic of), Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, Korea, Korea, Democratic People's Rep, Kuwait, Kyrgyzstan, Lao People's Democratic Republ, Latvia, Lebanon, Lesotho, Liberia, Libyan Arab Jamahiriya, Liechtenstein, Lithuania, Luxembourg, Macau, Macedonia, The Former Yugoslav, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Martinique, Mauritania, Mauritius, Mayotte, Mexico, Micronesia, Federated States o, Moldova, Republic of, Monaco, Mongolia, Montserrat, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Netherlands, Netherlands Antilles, New Caledonia, New Zealand, Nicaragua, Niger, Nigeria, Niue, Norfolk Island, Northern Mariana Islands, Norway, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Pitcairn, Poland, Portugal, Puerto Rico, Qatar, Reunion, Romania, Russia, Russian Federation, Rwanda, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadin, Samoa, San Marino, Sao Tome and Principe, Saudi Arabia, Senegal, Seychelles, Sierra Leone, Singapore, Slovakia (Slovak Republic), Slovenia, Solomon Islands, Somalia, South Africa, South Georgia and the South Sa, Spain, Sri Lanka, St. Helena, St. Pierre and Miquelon, Sudan, Suriname, Svalbard and Jan Mayen Islands, Swaziland, Sweden, Switzerland, Syrian Arab Republic, Taiwan, Tajikistan, Tanzania, United Republic of, Thailand, Togo, Tokelau, Tonga, Trinidad and Tobago, Tunisia, Turkey, Turkmenistan, Turks and Caicos Islands, Tuvalu, Uganda, Ukraine, United Arab Emirates, United Kingdom, United States Minor Outlying I, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, Virgin Islands (British), Virgin Islands (U.S.), Wallis and Futuna Islands, Western Sahara, Yemen, Yugoslavia, Zambia, Zimbabwe
    Adoption of Biosimilars in Oncology
    Release Date:
    Partner:

    The National Comprehensive Cancer Network® (NCCN)

    Review Process: Expert Review Panel
    Research Oncology USA
    Improving Disparities in Rheumatoid Arthritis Health Care in Post COVID-19 Era in memory of Cinzia Curiale
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Liechtenstein, Luxembourg, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom
    Management of Non-Communicable Diseases (NCD) for Health Care Providers
    Release Date:
    Review Process: Pfizer Internal
    Education Internal Medicine Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Holy See (Vatican City State), Hungary, Iceland, Ireland, Italy, Japan, Kazakhstan, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, The Former Yugoslav, Malta, Moldova, Republic of, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Slovakia (Slovak Republic), Slovenia, Spain, Sweden, Switzerland, Turkey, USA, Ukraine, United Kingdom
    Continuity of Care: Education for Rheumatology Patients
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Assessment of on-time immunization coverage in children under 2 years of age in Canada
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines Canada
    Optimal Early Therapy Management in CML
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology Canada, USA
    Addressing Racial Disparities in Cancer Care
    Release Date:
    Partner: American Cancer Society
    Review Process: Expert Review Panel
    Quality Improvement Oncology USA
    Addressing Knowledge Gaps in Growth Hormone Deficiency
    Release Date:
    Review Process: Pfizer Internal
    Education Rare Disease USA
    Telehealth in Postmenopausal Patient Care
    Release Date:
    Review Process: Pfizer Internal
    Education Internal Medicine USA